Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
243 results about "Catenin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells. The first two catenins that were identified became known as α-catenin and β-catenin. α-Catenin can bind to β-catenin and can also bind actin. β-Catenin binds the cytoplasmic domain of some cadherins. Additional catenins such as γ-catenin and δ-catenin have been identified. The name "catenin" was originally selected ('catena' means 'chain' in Latin) because it was suspected that catenins might link cadherins to the cytoskeleton.
Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components.
Owner:SAMUMED LLC
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
Owner:ALLERGAN SALES LLC
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Owner:BIOSPLICE THERAPEUTICS INC
Methods of identifying and isolating stem cells and cancer stem cells
InactiveUS7217568B2AlterationEasy to analyze and useMicrobiological testing/measurementArtificial cell constructsHematopoietic cellCancer cell
Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
Owner:MEREO BIOPHARMA 5 INC
Beta-catenin targeting peptides and uses thereof
InactiveUS20140005118A1Increase the helical character of peptidesIncrease productionPeptide/protein ingredientsPeptide preparation methodsDiseaseMedicine
The invention relates to β-catenin targeting peptides comprising an a-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive β-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Compositions and methods for treating and diagnosing cancer
ActiveUS8158758B2Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsBeta-cateninRSPO1
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
Owner:MEREO BIOPHARMA 5 INC
Generation of cardiomyocytes from human pluripotent stem cells
ActiveUS20130189785A1Artificial cell constructsSkeletal/connective tissue cellsProgenitorInduced pluripotent stem cell
Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
Owner:ONCOMED PHARMA
Therapeutic peptides for the treatment of metastatic cancer
InactiveUS20060293234A1Invasiveness is thereby reduced and retardedVirusesPeptide/protein ingredientsLymphatic SpreadBinding site
Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and / or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.
Owner:ARIZONA CANCER THERAPEUTICS
Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
InactiveUS7563825B1Improve bindingIncreased proliferationBiocideOrganic chemistryBeta-cateninCell growth
Methods and agents are disclosed for modulating the interaction of β-catenin or γ-catenin with CBP or p300. Agents that increase the binding of CBP to β-catenin are associated with enhancing the β-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells.
Owner:JW PHARMA CORP
Serum-free expansion of cells in culture
InactiveUS20070128669A1Enhanced interactionReduce interactionCompound screeningApoptosis detectionSerum igeSerum free
Methods and agents are disclosed for modulating the interaction of β-catenin or γ-catenin with CBP or p300. Agents that increase the binding of CBP to β-catenin are associated with enhancing the β-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells, as well as embryonic stem cells.
Owner:JW PHARMA CORP
Pharmaceutical compositions to treat fibrosis
InactiveUS20130274215A1Prevents and reduces fibrosisBiocideCarbohydrate active ingredientsMedicineΒ catenin signaling
The present invention provides methods for the prevention, treatment and / or amelioration of fibrosis or fibrotic conditions. The present invention further provides small molecule inhibitors of Wnt- and TGF-p-mediated β-catenin signaling to prevent, treat and / or ameliorate fibrosis or fibrotic conditions. Kits comprising small molecule inhibitors of Wnt- and TGF-p-mediated β-catenin signaling and methods of identifying small molecule inhibitors of Wnt- and TGF-p-mediated β-catenin signaling are also provided.
Owner:FATE THERAPEUTICS
Bipartite T-cell factor (Tcf)-responsive promoter
InactiveUS20030228285A1High activityValid choiceBiocidePeptide/protein ingredientsBeta-cateninCancer therapy
The present invention is directed to methods and compositions for cancer therapy, particularly cancers resulting from a defective Wnt / beta-catenin signaling pathway. In specific embodiments, a T-cell factor (Tcf)-responsive promoter regulating expression of a therapeutic gene is administered to an individual having the cancer. In a specific embodiment, the Tcf-responsive promoter comprises a minimal CMV promoter and is present on an adenovirus vector. The promoter regulates expression of a therapeutic gene.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Wnt as a factor for cardiac myogenesis
InactiveUS20050043260A1Restore structural integrityEffective amountGenetic material ingredientsSkeletal/connective tissue cellsMyogenesisΒ catenin signaling
The present invention relates to the fields of cell biology, molecular biology, and medicine. More specifically, the invention is directed to generating cardiomyocyte cells from non-cardiomyocyte cells by enhancing the activation of the Wnt / β-catenin signaling pathway. The cardiomyocyte cells that are generated in the present invention are then used as cardiac disease therapy.
Owner:BAYLOR COLLEGE OF MEDICINE
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and / or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and / or compositions in the treatment of subjects having a neurological disease and / or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and / or Chir99021 in the treatment of subjects having a neurological disease and / or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
Owner:MASSACHUSETTS INST OF TECH +1
beta- and gamma-diketones and gamma-hydroxyketones as WNT/beta-catenin signaling pathway activators
ActiveUS8609717B2Increasing cell and tissue regenerationIncrease cell and tissue regenerationBiocideSenses disorderDiseaseBeta-catenin
Owner:BIOSPLICE THERAPEUTICS INC
Compounds for the modulation of beta-catenin expression
InactiveUS20090203137A1Facilitate entryOrganic active ingredientsSugar derivativesMedical disorderOligomer
The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
Owner:ENZON PHARM INC +1
Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, by, for example, inhibiting Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis. One or more of these steps is performed under defined, albumin-free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND
Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
ActiveUS20140113857A1Improved pharmacokinetic propertiesGood acid stabilityPeptide/protein ingredientsImmunoglobulinsHuman cancerΒ catenin signaling
The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to β-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9 / β-catenin interaction, and thereby interfering with deregulated Wnt / β-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.
Owner:DANA FARBER CANCER INST INC
Compounds for the modulation of beta-catenin expression
InactiveUS20090005335A1Facilitate entryOrganic active ingredientsSugar derivativesMedical disorderOligomer
The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
Owner:SANTARIS PHARMA AS
Generation of cardiomyocytes from human pluripotent stem cells
ActiveUS8951798B2Artificial cell constructsSkeletal/connective tissue cellsProgenitorInduced pluripotent stem cell
Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND
RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA)
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond expressed / synthetic to the modulation of PHD2 gene expression and / or activity, and / or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short inter-fering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsR-NA), micro-RNA (miRNA), and short hair-pin RNA (shRNA) molecules that are capa-ble of mediating or that mediate RNA inter-ference (RNAi) against PHD2 gene expres-sion.
Owner:SIRNA THERAPEUTICS INC
Methods and compositions for modulating beta-catenin phosphorylation
The present invention provides modulators of β-catenin phosphorylation. More specifically, the present invention provides inhibitors and enhancers of β-catenin Serine 45 (S45) phosphorylation. Examples of inhibitors provided by the invention are the proteins Dishevelled (Dvl), Wnt, phosphatase PP2A and CKI7. Examples of enhancers of beta-catenin phosphorylation are phosphatase inhibitors and proteins that promote β-catenin acetylation, like FRAT1. In addition, the present invention provides compositions and uses of the modulators of the invention, specifically for the treatment of cancer, as well as a method for screening such modulators.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Isoxazole Derivatives and Use Thereof
Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt / β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.
Owner:BIOPHARM
Application of protein Bach1 to preparation of cell Wnt signaling pathway inhibitor
The invention belongs to the fields of biotechnology and medicine, and relates to application of protein Bach1 to inhibition of a cell classic Wnt signaling pathway. The invention provides that the Bach1 is a medicine target for intervening diseases related to an abnormal Wnt signaling pathway, such as vasculogenesis, cancers, abnormal cell proliferation, Alzheimer's disease and osteoarthritis. The protein Bach1 directly blocks beta-catenin / TFC protein binding to interfere formation of the transcription complex so that Wnt signaling pathway target gene expression is inhibited; the cell proliferation is inhibited and apoptosis is induced. The application provided by the invention provides a new target for screening a medicine for treating the diseases related to the abnormal Wnt signaling pathway; furthermore, the protein Bach1 can be used for preparing a cell Wnt signaling pathway inhibitor and preparing a medicine for preventing and / or treating the diseases related to the abnormal Wnt signaling pathway.
Owner:FUDAN UNIV
Methods and compositions for the diagnosis and treatment of thyroid cancer
InactiveUS20120252022A1Microbiological testing/measurementBiological material analysisBeta-cateninOncology
Owner:WALFISH PAUL +1
Combination therapy using c-met inhibitor and beta-catenin inhibitor
ActiveUS20150071930A1Good curative effectOrganic active ingredientsBiocideBeta-cateninCombination therapy
A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.
Owner:SAMSUNG ELECTRONICS CO LTD
Vector composition for indicating active state of Wnt signal in cell by using BiFC (Bimolecular Fluorescence Complementation) and application of vector composition
InactiveCN104004098ASimple methodEfficient formationBiological testingHybrid peptidesBeta-cateninActive state
The invention discloses a system for indicating the active state of a Wnt signal in a cell by using BiFC (Bimolecular Fluorescence Complementation) and application of the vector composition. The invention provides a fusion protein group which consists of fusion protein A and fusion protein B, wherein the fusion protein A comprises a core effector beta-catenin fragment and a fluorescent protein fragment A located at a fragment C of the core effector beta-catenin fragment; the fusion protein B comprises a transcription factor (TCF) and a fluorescent protein fragment B located at a fragment N of the TCF. Proved by experiments, a complex formed by the core effector beta-catenin and the TCF in a Wnt signal channel is visualized by using a strategy on the basis of BiFC, so that the active state of Wnt in the cell is directly displayed; a BiFC system is used for instantaneously transfecting cells or constructing a stable expression cell line, so that specific signals formed in a cell nucleus can be observed and can specifically display and reflect the active state of the Wnt signal channel in a living cell and variation thereof.
Owner:TSINGHUA UNIV
Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
A series of oxazole and thiazole compounds are shown herein to be small molecule inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of β-cat oxazole and thiazole compounds are disclosed that have a formula represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and others.
Owner:NEW YORK UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com